Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2

  • Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. doi: 10.1016/j.bmcl.2009.08.066.
Mark Andrews  1 ,  Alan Brown ,  Jean-Yves Chiva ,  David Fradet ,  David Gordon ,  Mark Lansdell ,  Malcolm MacKenny
Affiliations
  • 1. Discovery Chemistry, Pfizer Global Research and Development, Sandwich, United Kingdom.
PMID: 19740658 DOI: 10.1016/j.bmcl.2009.08.066
Abstract

A second wave of potential SSRIs with high ease of synthetic accessibility were designed based on the reported selective serotonin re-uptake inhibitor litoxetine and our own previous work in this area. Preparation and subsequent optimisation yielded a range of potent and highly selective SSRIs.